✦ LIBER ✦

Optimal dose adjustment in orthopedic patients beginning warfarin therapy

✍ Scribed by P. A. Jacobsen; G. R. Grice; P. E. Milligan; S. K. Gatchel; E. Deych; C. S. Eby; R. S. Burnett; J. C. Clohisy; R. L. Barrack; B. F. Gage

Book ID: 106544011
Publisher: Springer US
Year: 2007
Tongue: English
Weight: 86 KB
Volume: 25
Category: Article
ISSN: 0929-5305
DOI: 10.1007/s11239-007-0144-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacogenetic dose adjustments in orth

Pharmacogenetic dose adjustments in orthopedic patients beginning warfarin therapy

✍ Petra A. Jacobsen-Lenzini; Charles S. Eby; Paul E. Milligan; Gloria R. Grice; El 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 89 KB

Initiation of oral anticoagulant therapy

Initiation of oral anticoagulant therapy in orthopedic and surgical patients: an algorithm compared with routine dosing

✍ P. van den Bemt; M. Beinema; E. van Roon; J. Sijtsma; W. Baars; H. Mencke; J. Br 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 106 KB

Lack of increase in postoperative compli

Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery

✍ Koichi Murata; Tadashi Yasuda; Hiromu Ito; Makoto Yoshida; Makoto Shimizu; Takas 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 189 KB

Potential Clinical and Economic Outcomes

Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy

✍ You, J H S; Tsui, K K N; Wong, R S M; Cheng, G 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 175 KB

Toxicity in standard melphalan–prednison

Toxicity in standard melphalan–prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustment

✍ Kristina Carlson; Martin Hjorth; Lene Meldgaard Knudsen; The Nordic Myeloma Stud 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

What is the optimal treatment volume in

What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?

✍ Arno J. Mundt; Philip P. Connell; David B. Mansur 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

To determine the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy (HDCT) and radiation therapy (RT), failure sites were reviewed in 56 patients. Twenty-one (38%) received involved-field RT (IFRT) before or after HDCT encompassing sites of prior disease. Failur